|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study
|
|
Siamak Daneshmand, MD
|
| Ashish Kamat welcomes Siamak (Sia) Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy.
|
|
|
|
|
|
|
|
|
|
|
|
|
Urban vs Rural Bladder Cancer Mortality: 20-Year Trend Analysis
|
|
Jason Brown, MD, PhD
|
| Sam Chang interviews Jason Brown about research on disparities in bladder cancer mortality between urban and rural settings from 2000 to 2020. Dr. Brown presents findings showing a significant decline in bladder cancer mortality in urban areas, particularly large metropolitan centers, while rates remain unchanged in rural areas.
|
|
|
|
|
|
|
|
|
|
|
|
|
Disparities and Underutilization of Aggressive Therapy in Muscle-Invasive Bladder Cancer: An NCDB Analysis
|
|
James E. Ferguson III, MD, PhD
|
| Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson's team delved into the National Cancer Database, revealing that a significant percentage of patients do not receive aggressive treatments post-TURBT, with factors such as age, comorbidity, race, insurance status, and treatment facility type playing crucial roles in the variance of care.
|
|
|
|
|
|
|
|
|
|
|
|
| Association of Age with Non-Muscle-Invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? - Beyond the Abstract
|
| Niyati Lobo, MD, & Ashish Kamat, MD, MBBS
|
| Bladder cancer is primarily a disease of the elderly and advanced age is a risk factor for progression to muscle-invasive disease. This is reflected in the EAU guidelines which recognize age >70 as an independent prognostic factor.
|
|
|
|
|
|
| Racial and Sex Differences in Tumor Genomics in Urothelial Carcinoma - Expert Commentary
|
| Bishoy M. Faltas, MD
|
| Various studies have demonstrated significant differences in bladder cancer mortality across sex and race. These are partly related to differences in social and environmental factors, in addition to varying degrees of access to healthcare.
|
|
|
|
|
|
|
|
|
|
|
| Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials
|
| Cheryl T. Lee, MD
|
| In this Keynote Lecture, Dr. Cheryl Lee discusses increasing patient representation in genitourinary malignancy trials. Based on a National Academy 2022 Consensus Report, lack of representation results in several issues with clinical trials.
|
|
|
|
|
|
| Identifying Individual and Community-Level Drivers of Disparities in Bladder Cancer Clinical Trials Participation
|
| Rishi Sekar, MD
|
| At the 2024 Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank annual meeting, Dr. Rishi Sekar, the Patient-Centered Clinical Research Young Investigator Awardee, discussed his work evaluating individual and community-level drivers of disparities in bladder cancer clinical trials participation.
|
|
|
|
|
|
| Impact of Rural Location on Receipt of Standard of Care Treatment and Survival for Locally Advanced Bladder Cancer in Louisiana
|
| Ashley Foret
|
| Ashley Foret discusses the impact of rural location on receipt of standard of care treatment and survival for locally advanced bladder cancer in Louisiana. Using the Louisiana Tumor Registry, Dr. Foret identified AJCC stage II or III, microscopically confirmed bladder cancer diagnoses in Louisiana residents between 2010 and 2020.
|
|
|
|
|
|
| Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin - Beyond the Abstract
|
| Evangelia Vlachou, MD & Vivek Nimgaonkar, MD
|
| In a recently published manuscript in Clinical Genitourinary Cancer, our team investigated differences in EVCE frequency between Black and White patients in two retrospective cohorts of EV-treated patients, an institutional cohort of patients seen at the Johns Hopkins Hospital (JH) and a national cohort of patients in the Flatiron Health (FH) deidentified electronic health record-derived database.
|
|
|
|
|
|
